Fig. 5.

Combination CP1 and anti-PD-1 immunotherapy is efficacious in treating a novel orthotopic advanced prostate cancer model. In vitro comparison of Myc-CaP and Myc-CaP PTEN KO cell lines by a western blot (p-AKT = phosphorylated AKT, AR = androgen receptor), b flow cytometry, c growth rate by MTS assays in normal media (10%), low serum (1%), and charcoal stripped (C.S.) FBS, performed in triplicates, and as d 3-dimensional organoids, performed in sextuplicates. Myc-CaP PTEN KO e Kaplan–Meier survival curve, n = 7 mice/experimental group, performed in two independent experiments, and f tumor volumes, n = 3–6 mice/experimental group. Data represented as mean ± S.E.M. Statistical significance was determined by c two-way ANOVA, d two-tailed Student’s t-test, e Log-rank test, f one-way ANOVA. *P < 0.05, **P < 0.01, ***P < 0.001